US equities
|
SPCX
$166.68
▲+4.85%
NVDA
$236.62
▲+1.14%
MU
$1,064.16
▼-1.00%
TSLA
$377.77
▲+1.94%
MSFT
$525.54
▲+1.55%
SNDK
$1,711.54
▼-0.49%
INTC
$117.14
▼-1.84%
META
$745.75
▲+2.43%
SPCX
$166.68
▲+4.85%
NVDA
$236.62
▲+1.14%
MU
$1,064.16
▼-1.00%
TSLA
$377.77
▲+1.94%
MSFT
$525.54
▲+1.55%
SNDK
$1,711.54
▼-0.49%
INTC
$117.14
▼-1.84%
META
$745.75
▲+2.43%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Annexon, Inc. - common stock
(NQ:
ANNX
)
4.179
-0.011 (-0.26%)
Delayed Quote
Updated: 11:44 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Annexon, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 17, 2025
Via
Benzinga
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 03, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
From
Annexon Biosciences
Via
GlobeNewswire
ANNX Stock Earnings: Annexon Meets EPS for Q2 2024
↗
August 12, 2024
ANNX stock results show that Annexon met analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
February 13, 2025
Data Reinforce Neuroprotective Effect of C1q Blockade with ANX007 Against Inflammation and Neuronal Damage
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
January 13, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
January 10, 2025
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
December 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
December 05, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
November 14, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
November 13, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
October 21, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
October 15, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
September 09, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
September 03, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Participate in Upcoming September Investor Conferences
August 29, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
August 12, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
August 05, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
↗
July 12, 2024
Via
Benzinga
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
July 11, 2024
From
Annexon Biosciences
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
July 10, 2024
Via
Benzinga
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
June 25, 2024
From
Annexon Biosciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
